German Center for Cardiac and Vascular Research (DZHK) Standort Rhein-Main, Department of Cardiology, University Medical Center Mainz, 55131 Mainz, Germany.
Cells. 2022 Jun 30;11(13):2094. doi: 10.3390/cells11132094.
Coronary stents are among the most common therapies worldwide. Despite significant improvements in the biocompatibility of these devices throughout the last decades, they are prone, in as many as 10-20% of cases, to short- or long-term failure. In-stent restenosis is a multifactorial process with a complex and incompletely understood pathophysiology in which inflammatory reactions are of central importance. This review provides a short overview for the clinician on the cellular types responsible for restenosis with a focus on the role of endothelial progenitor cells. The mechanisms of restenosis are described, along with the cell-based attempts made to prevent it. While the focus of this review is principally clinical, experimental evidence provides some insight into the potential implications for prevention and therapy of coronary stent restenosis.
冠状动脉支架是全球最常见的治疗方法之一。尽管在过去几十年中,这些设备的生物相容性有了显著提高,但仍有多达 10-20%的病例存在短期或长期失败的风险。支架内再狭窄是一种多因素的过程,其病理生理学复杂且尚未完全被理解,其中炎症反应起着至关重要的作用。本篇综述为临床医生提供了一个关于导致再狭窄的细胞类型的简要概述,重点介绍了内皮祖细胞的作用。本文还描述了再狭窄的机制,以及为预防再狭窄而进行的基于细胞的尝试。虽然本篇综述的重点主要是临床方面的,但实验证据为预防和治疗冠状动脉支架内再狭窄提供了一些潜在的见解。